Prostaglandin E(2) inhibits IL-18-induced ICAM-1 and B7.2 expression through EP2/EP4 receptors in human peripheral blood mononuclear cells.
Costimulatory molecules play important roles in immune responses. In the present study we investigated the effects of PGE(2) on the expression of ICAM-1, B7.1, and B7.2 on monocytes in IL-18-stimulated PBMC using FACS analysis. Addition of PGE(2) to PBMC inhibited ICAM-1 and B7.2 expression elicited by IL-18 in a concentration-dependent manner. We examined the involvement of four subtypes of PGE(2) receptors, EP1, EP2, EP3, and EP4, in the modulatory effect of PGE(2) on ICAM-1 and B7.2 expression elicited by IL-18, using subtype-specific agonists. ONO-AE1-259-01 (EP2R agonist) inhibited IL-18-elicited ICAM-1 and B7.2 expression in a concentration-dependent manner with a potency slightly less than that of PGE(2), while ONO-AE1-329 (EP4R agonist) was much less potent than PGE(2). The EP2/EP4R agonist 11-deoxy-PGE(1) mimicked the effect of PGE(2) with the same potency. ONO-D1-004 (EP1R agonist) and ONO-AE-248 (EP3R agonist) showed no effect on IL-18-elicited ICAM-1 or B7.2 expression. These results indicated that EP2 and EP4Rs were involved in the action of PGE(2). Dibutyryl cAMP and forskolin down-regulated ICAM-1 and B7.2 expression in IL-18-stimulated monocytes. As EP2 and EP4Rs are coupled to adenylate cyclase, we suggest that PGE(2) down-regulates IL-18-induced ICAM-1 and B7.2 expression in monocytes via EP2 and EP4Rs by cAMP-dependent signaling pathways. The fact that anti-B7.2 as well as anti-ICAM-1 Ab inhibited IL-18-induced cytokine production implies that PGE(2) may modulate the immune response through regulation of the expression of particular adhesion molecules on monocytes via EP2 and EP4Rs.
Takahashi
Hideo K
HK
Department of Pharmacology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
Iwagaki
Hiromi
H
Yoshino
Tadashi
T
Mori
Shuji
S
Morichika
Toshihiko
T
Itoh
Hideyuki
H
Yokoyama
Minori
M
Kubo
Shinichiro
S
Kondo
Eisaku
E
Akagi
Tadaatsu
T
Tanaka
Noriaki
N
Nishibori
Masahiro
M
D000906:Antibodies / Q000494:pharmacology; D015703:Antigens, CD / Q000096:biosynthesis*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen; D001769:Blood / Q000276:immunology; D003994:Bucladesine / Q000494:pharmacology; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis*; D020382:Interleukin-18 / Q000037:antagonists & inhibitors*; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D018078:Receptors, Prostaglandin E / Q000819:agonists / Q000378:metabolism*; D058307:Receptors, Prostaglandin E, EP2 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype
D000906:Antibodies; D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497964:CD86 protein, human; D020382:Interleukin-18; D008562:Membrane Glycoproteins; C545644:PTGER2 protein, human; C545650:PTGER4 protein, human; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype; D018799:Intercellular Adhesion Molecule-1; D005576:Colforsin; D003994:Bucladesine; D015232:Dinoprostone